The challenge of developing robust drugs to overcome resistance

被引：18

作者：

Anderson, Amy C. ^{[1
,2
]}

Pollastri, Michael P. ^{[1
,3
]}

Schiffer, Celia A. ^{[1
,4
]}

Peet, Norton P. ^{[1
,5
]}

机构：

[1] Univ Massachusetts, Sch Med, Inst Drug Resistance, Worcester, MA 01605 USA

[2] Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA

[3] Northeastern Univ, Dept Chem & Chem Biol, Egan Res Ctr 417, Boston, MA 02115 USA

[4] Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA

[5] Microbiotix Inc, Worcester, MA 01605 USA

来源：

DRUG DISCOVERY TODAY | 2011年 / 16卷 / 17-18期

关键词：

HIV-1 PROTEASE INHIBITORS; AUREUS DIHYDROFOLATE-REDUCTASE; SUBSTRATE-ENVELOPE HYPOTHESIS; TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; CELL LUNG-CANCER; STAPHYLOCOCCUS-AUREUS; DNA GYRASE; BCR-ABL; ESCHERICHIA-COLI;

D O I：

10.1016/j.drudis.2011.07.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug resistance is problematic in microbial disease, viral disease and cancer. Understanding at the outset that resistance will impact the effectiveness of any new drug that is developed for these disease categories is imperative. In this Feature, we detail approaches that have been taken with selected drug targets to reduce the susceptibility of new drugs to resistance mechanisms. We will also define the concepts of robust drugs and resilient targets, and discuss how the design of robust drugs and the selection of resilient targets can lead to successful strategies for combating resistance.

引用

页码：755 / 761

页数：7

共 88 条

[1] Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 Ligands [J].

Ali, Akbar ;

Reddy, G. S. Kiran Kumar ;

Cao, Hong ;

Anjum, Saima Ghafoor ;

Nalam, Madhavi N. L. ;

Schiffer, Celia A. ;

Rana, Tariq M. .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (25) :7342-7356

[2] THE 43-KILODALTON N-TERMINAL FRAGMENT OF THE DNA GYRASE-B PROTEIN HYDROLYZES ATP AND BINDS COUMARIN DRUGS [J].

ALI, JA ;

JACKSON, AP ;

HOWELLS, AJ ;

MAXWELL, A .

BIOCHEMISTRY, 1993, 32 (10) :2717-2724

[3] HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants [J].

Altman, Michael D. ;

Ali, Akbar ;

Reddy, G. S. Kiran Kumar ;

Nalam, Madhavi N. L. ;

Anjum, Saima Ghafoor ;

Cao, Hong ;

Chellappan, Sripriya ;

Kairys, Visvalclas ;

Fernandes, Miguel X. ;

Gilson, Michael K. ;

Schiffer, Celia A. ;

Rana, Tariq M. ;

Tidor, Bruce .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (19) :6099-6113

[4] Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease [J].

Altman, Michael D. ;

Nalivaika, Ellen A. ;

Prabu-Jeyabalan, Moses ;

Schiffer, Celia A. ;

Tidor, Bruce .

PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2008, 70 (03) :678-694

[5] New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine [J].

Angehrn, P ;

Buchmann, S ;

Funk, C ;

Goetschi, E ;

Gmuender, H ;

Hebeisen, P ;

Kostrewa, D ;

Link, H ;

Luebbers, T ;

Masciadri, R ;

Nielsen, J ;

Reindl, P ;

Ricklin, F ;

Schmitt-Hoffmann, A ;

Theil, FP .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) :1487-1513

[6]

Annedi S C, 2001, Curr Opin Investig Drugs, V2, P752

[7]

[Anonymous], Stanford HIV Drug Resistance Database

[8]

[Anonymous], HEP C

[9] Activation of tyrosine kinases by mutation of the gatekeeper threonine [J].

Azam, Mohammad ;

Seeliger, Markus A. ;

Gray, Nathanael S. ;

Kuriyan, John ;

Daley, George Q. .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2008, 15 (10) :1109-1118

[10] Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults [J].

Bartlett, JA ;

DeMasi, R ;

Quinn, J ;

Moxham, C ;

Rousseau, F .

AIDS, 2001, 15 (11) :1369-1377

← 1 2 3 4 5 6 7 8 9 →